Tekmira is a leader in the development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (RNAi). Tekmira's three lead RNAi product candidates target cholesterol management, cancer and Ebola infection. In addition to its pipeline of products, Tekmira also has collaborative partnerships with leading companies in the RNAi field.
May 17, 2013
Tekmira Announces Election of Directors
May 14, 2013 at 4:00 PM ET
Tekmira Provides Corporate Update and Announces First Quarter Results
May 14, 2013 at 2:00 PM PT
Tekmira's 2013 AGM / Proxy Materials